标题
Overview of the relevance of PI3K pathway in HR-positive breast cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 30, Issue Supplement_10, Pages x3-x11
出版商
Oxford University Press (OUP)
发表日期
2019-08-12
DOI
10.1093/annonc/mdz281
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression
- (2019) Eneda Toska et al. Cell Reports
- Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
- (2018) Dimitrios Zardavas et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
- (2018) Utthara Nayar et al. NATURE GENETICS
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
- (2017) Eneda Toska et al. SCIENCE
- Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
- (2017) Jordi Rodon et al. Cancer Discovery
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
- (2016) Pau Castel et al. CANCER CELL
- Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers
- (2016) Sarah Naomi Olsen et al. Cancer Discovery
- Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
- (2015) Carlotta Costa et al. CANCER CELL
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Progesterone receptor modulates ERα action in breast cancer
- (2015) Hisham Mohammed et al. NATURE
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
- (2014) Vandana G. Abramson et al. BREAST CANCER RESEARCH AND TREATMENT
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
- (2014) Lydia W.T. Cheung et al. CANCER CELL
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis
- (2014) Bo Pang et al. Scientific Reports
- Mouse models ofPIK3CAmutations: one mutation initiates heterogeneous mammary tumors
- (2013) Shany Koren et al. FEBS Journal
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry
- (2011) Jonathan Clark et al. NATURE METHODS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Cooperative interaction between retinoic acid receptor- and estrogen receptor in breast cancer
- (2010) C. S. Ross-Innes et al. GENES & DEVELOPMENT
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
- (2009) Krishna M. Vasudevan et al. CANCER CELL
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
- (2008) Mathieu Lupien et al. CELL
- S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
- (2008) Rachel L. Yamnik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
- (2008) Aleix Prat et al. Nature clinical practice. Oncology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started